Thus, translational studies focusing on the therapeutic targeting of tau, especially if involving mechanisms preventing tau spread, should include models that better approximate the environment of clinical AD by considering the interactions between Aβ and tau. This evidence concerns the gene MAPT and Alzheimer disease.